PCSK9 MaB (Proprotein Convertase Subtilisin/Kexin Type 9Inhibitor) may reduce the occurrence of major adverse cardiovascular events(MACEs) in patients diagnosed with acute coronary syndrome (ACS). This evidence concerns the gene PCSK9 and acute coronary syndrome.